Save information for later
Sign Up

Learn About Dystrophic Epidermolysis Bullosa

What is the definition of Dystrophic Epidermolysis Bullosa?

Dystrophic epidermolysis bullosa is one of the major forms of a group of conditions called epidermolysis bullosa. Epidermolysis bullosa cause the skin to be very fragile and to blister easily. Blisters and skin erosions form in response to minor injury or friction, such as rubbing or scratching. The signs and symptoms of dystrophic epidermolysis bullosa vary widely among affected individuals. In mild cases, blistering may primarily affect the hands, feet, knees, and elbows. Severe cases of this condition involve widespread blistering that can lead to vision loss, scarring, and other serious medical problems.

What are the causes of Dystrophic Epidermolysis Bullosa?

Mutations in the COL7A1 gene cause all forms of dystrophic epidermolysis bullosa. This gene provides instructions for making a protein that forms the pieces (subunits) of a larger protein called type VII collagen. Collagens are proteins that give structure and strength to connective tissues, such as skin, tendons, and ligaments, throughout the body. Type VII collagen plays an important role in strengthening and stabilizing the skin. It is the main component of structures called anchoring fibrils, which anchor the top layer of skin, called the epidermis, to an underlying layer called the dermis.

How prevalent is Dystrophic Epidermolysis Bullosa?

Considered together, the prevalence of recessive and dominant dystrophic epidermolysis bullosa is estimated to be 3.3 per million people.

Is Dystrophic Epidermolysis Bullosa an inherited disorder?

Recessive dystrophic epidermolysis bullosa (RDEB-sev gen and RDEB-gen and -loc) is inherited in an autosomal recessive pattern. Autosomal recessive inheritance means that both copies of the COL7A1 gene in each cell have mutations. Most often, the parents of an individual with an autosomal recessive condition each carry one copy of the mutated gene, but do not show signs and symptoms of the condition.

Who are the top Dystrophic Epidermolysis Bullosa Local Doctors?
Paris, FR 

Alain Hovnanian practices in Paris, France. Hovnanian and is rated as an Elite expert by MediFind in the treatment of Dystrophic Epidermolysis Bullosa. His top areas of expertise are Netherton Syndrome, Olmsted Syndrome, Dystrophic Epidermolysis Bullosa, and Epidermolysis Bullosa.

Freiburg, BW, DE 

Leena Tuderman-Bruckner practices in Freiburg, Germany. Tuderman-Bruckner and is rated as an Elite expert by MediFind in the treatment of Dystrophic Epidermolysis Bullosa. Her top areas of expertise are Epidermolysis Bullosa, Dystrophic Epidermolysis Bullosa, Bullae, Kindler Syndrome, and Bone Marrow Transplant.

 
 
 
 
Learn about our expert tiers
Learn More

Birmingham Children's Hospital NHS FT

Birmingham, ENG, GB 

Jemima Mellerio practices in Birmingham, United Kingdom. Mellerio and is rated as an Elite expert by MediFind in the treatment of Dystrophic Epidermolysis Bullosa. Her top areas of expertise are Epidermolysis Bullosa, Dystrophic Epidermolysis Bullosa, Dowling-Meara Epidermolysis Bullosa Simplex, Dominant Dystrophic Epidermolysis Bullosa, and Gastrostomy.

What are the latest Dystrophic Epidermolysis Bullosa Clinical Trials?
A Natural History Study of Corneal Abrasions in Patients With Dystrophic Epidermolysis Bullosa (DEB)

Summary: This study is a non-interventional, observational study that will evaluate the natural history of corneal abrasions in patients with Dystrophic Epidermolysis Bullosa (DEB).

Match to trials
Find the right clinical trials for you in under a minute
Get started
A Safety Study of the Administration of Mesenchymal Stem Cell Extracellular Vesicles in the Treatment of Dystrophic Epidermolysis Bullosa Wounds

Summary: INVESTIGATIONAL PRODUCT: AGLE-102 is an allogeneic derived extracellular vesicle (EV) product derived from normal donor mesenchymal stem cells (MSCs). INDICATION AND RATIONALE: The aim of the study is to assess the safety and efficacy of AGLE-102 in the treatment of lesions in subjects with Epidermolysis Bullosa (EB). STUDY DESIGN: This is a phase 1/2A, non randomized, multi-center, study to asses...

Who are the sources who wrote this article ?

Published Date: February 01, 2020
Published By: National Institutes of Health